MINNEAPOLIS, Oct. 27, 2016 /PRNewswire/ -- Cogentix
Medical, Inc. (NASDAQ: CGNT), a medical device company that
develops, manufactures and markets innovative proprietary products
for the urology market, will release financial results for the
third quarter ended September 30,
2016 after the market close on Tuesday, November 8, 2016.
The Company will host a conference call and webcast to discuss
these results on Tuesday, November 8,
2016 at 4:30 p.m. Eastern Time
(3:30 p.m. Central Time).
Darin Hammers, President and Chief
Executive Officer, will host the event along with Brett Reynolds, Chief Financial Officer.
Individuals wishing to participate in the conference call should
dial 877-303-1595 with the conference ID number 2782119. To access
a live webcast of the call, go to the investor relations section of
Cogentix Medical's website at ir.cogentixmedical.com.
An audio replay will be available for 30 days following the call
at 855-859-2056 with the conference ID number 2782119. An archived
webcast will also be available at ir.cogentixmedical.com.
About Cogentix Medical
Cogentix Medical, Inc.,
headquartered in Minnetonka,
Minnesota, with operations in New
York, Massachusetts,
The Netherlands and the
United Kingdom, is a global
medical device company. We design, develop, manufacture and market
products for flexible endoscopy with our unique product lines
featuring a streamlined visualization system and proprietary
sterile disposable microbial barrier, known as EndoSheath
technology, providing users with efficient and cost effective
endoscope turnover while enhancing patient safety. We also
commercialize the Urgent® PC Neuromodulation System, an FDA-cleared
device that delivers percutaneous tibial nerve stimulation (PTNS)
for the office-based treatment of overactive bladder (OAB). OAB is
a chronic condition that affects approximately 42 million U.S.
adults. The symptoms include urinary urgency, frequency and urge
incontinence. We also offer Macroplastique®, an injectable urethral
bulking agent for the treatment of adult female stress urinary
incontinence primarily due to intrinsic sphincter deficiency. For
more information on Cogentix Medical and our products, please visit
us at www.cogentixmedical.com. 'CGNT-G'
For Further Information:
Cogentix Medical, Inc.
Brett Reynolds, SVP and CFO
952-426-6152
EVC Group
Doug Sherk/Brian Moore (Investors)
415-652-9100/310-579-6199
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/cogentix-medical-to-report-third-quarter-results-on-november-8-2016-300352090.html
SOURCE Cogentix Medical, Inc.